DE2120995A1 - Verfahren zum Modifizieren interzellularer Reaktionen - Google Patents
Verfahren zum Modifizieren interzellularer ReaktionenInfo
- Publication number
- DE2120995A1 DE2120995A1 DE19712120995 DE2120995A DE2120995A1 DE 2120995 A1 DE2120995 A1 DE 2120995A1 DE 19712120995 DE19712120995 DE 19712120995 DE 2120995 A DE2120995 A DE 2120995A DE 2120995 A1 DE2120995 A1 DE 2120995A1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- acid
- groups
- compounds
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title description 6
- 230000004044 response Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- GSASOFRDSIKDSN-UHFFFAOYSA-N 6-[(5-carboxypyridin-2-yl)disulfanyl]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1SSC1=CC=C(C(O)=O)C=N1 GSASOFRDSIKDSN-UHFFFAOYSA-N 0.000 claims description 7
- 206010027476 Metastases Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000004606 Fillers/Extenders Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 67
- 125000003396 thiol group Chemical group [H]S* 0.000 description 26
- 239000002253 acid Substances 0.000 description 19
- 230000002093 peripheral effect Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000872 buffer Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 206010003445 Ascites Diseases 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241001061127 Thione Species 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- -1 heterocyclic amines Chemical class 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JUHUNQKORPPLMS-UHFFFAOYSA-N 2-[(3-carboxypyridin-2-yl)disulfanyl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1SSC1=NC=CC=C1C(O)=O JUHUNQKORPPLMS-UHFFFAOYSA-N 0.000 description 2
- JJNRRWXGTKBZGM-UHFFFAOYSA-N 4-[(2,6-dicarboxypyridin-4-yl)disulfanyl]pyridine-2,6-dicarboxylic acid Chemical compound OC(=O)C1=NC(C(=O)O)=CC(SSC=2C=C(N=C(C=2)C(O)=O)C(O)=O)=C1 JJNRRWXGTKBZGM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000883306 Huso huso Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- KTWIATYFXLGCQQ-UHFFFAOYSA-N 2-[(4-carboxypyridin-2-yl)disulfanyl]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(SSC=2N=CC=C(C=2)C(O)=O)=C1 KTWIATYFXLGCQQ-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- HTAOBWQHYXXCKR-UHFFFAOYSA-N 4-[(2-carboxypyridin-4-yl)disulfanyl]pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(SSC=2C=C(N=CC=2)C(O)=O)=C1 HTAOBWQHYXXCKR-UHFFFAOYSA-N 0.000 description 1
- GDNRXBCYGMSRBB-UHFFFAOYSA-N 6-(5-carboxypyridin-2-yl)sulfanylpyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1SC1=CC=C(C(O)=O)C=N1 GDNRXBCYGMSRBB-UHFFFAOYSA-N 0.000 description 1
- XAVCTYVSLHKLOD-UHFFFAOYSA-N 6-[(6-carboxypyridin-2-yl)disulfanyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(SSC=2N=C(C=CC=2)C(O)=O)=N1 XAVCTYVSLHKLOD-UHFFFAOYSA-N 0.000 description 1
- 101150018711 AASS gene Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 101150027751 Casr gene Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical compound OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SDNJNDFHCODQDQ-UHFFFAOYSA-N n-(2-ethylphenyl)-2-[[2-[(2-ethylphenyl)carbamoyl]phenyl]disulfanyl]benzamide Chemical compound CCC1=CC=CC=C1NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(=O)NC1=CC=CC=C1CC SDNJNDFHCODQDQ-UHFFFAOYSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NVONKHVIUAWOAO-UHFFFAOYSA-N pyridine-2,3,5-tricarboxylic acid Chemical compound OC(=O)C1=CN=C(C(O)=O)C(C(O)=O)=C1 NVONKHVIUAWOAO-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3487370A | 1970-05-05 | 1970-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2120995A1 true DE2120995A1 (de) | 1971-11-18 |
Family
ID=21879128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712120995 Pending DE2120995A1 (de) | 1970-05-05 | 1971-04-29 | Verfahren zum Modifizieren interzellularer Reaktionen |
Country Status (9)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2900964A1 (de) * | 1978-01-12 | 1979-07-19 | Davide Riccardo Grassetti | Arzneimittel mit einer anregenden wirkung |
| EP0194571B1 (de) * | 1985-03-12 | 1990-11-14 | Hoechst Aktiengesellschaft | Heterocyclische Disulfide, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| CA2299306C (en) * | 1997-08-05 | 2007-02-06 | Davide R. Grassetti | Antimutagenic agents |
| EP1383499B1 (en) | 2001-01-10 | 2013-03-06 | The GRASSETTI Family Trust | Method of immunomodulation using thione-forming disulfides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH69A (fr) * | 1889-01-09 | Charles Humbert Fils | Nouveau système de cadran lumineux pour montres de poche, pendules, horloges publiques, etc. | |
| CH70A (fr) * | 1888-11-15 | 1889-01-09 | Louis Carpano | Fraises à arrondir les roues d'horlogerie |
| CH71A (de) * | 1888-11-15 | 1889-06-13 | Th Hunziker | Apparat zum Absticken verlängerter Nädlinge für Handstickmaschinen |
| GB582638A (en) * | 1944-07-05 | 1946-11-22 | Glaxo Lab Ltd | A new anti-bacterial pyridine derivative and salts thereof |
| FR1265863A (fr) * | 1959-05-04 | 1961-07-07 | Olin Mathieson | Fongicides complexes contenant du molybdène utilisés notamment en agriculture |
| FR6075M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1965-09-20 | 1968-06-04 | ||
| GB1190268A (en) * | 1966-05-12 | 1970-04-29 | Nyegaard & Co As | Pyridine Derivatives |
| ZA703779B (en) * | 1969-06-12 | 1972-01-26 | Ici Ltd | Pesticidally active compounds and compositions containing them |
-
1971
- 1971-04-11 IL IL36587A patent/IL36587A/en unknown
- 1971-04-19 PH PH12380A patent/PH12181A/en unknown
- 1971-04-22 BE BE766123A patent/BE766123A/xx not_active IP Right Cessation
- 1971-04-29 DE DE19712120995 patent/DE2120995A1/de active Pending
- 1971-05-04 ZA ZA712898A patent/ZA712898B/xx unknown
- 1971-05-05 GB GB1331771*[A patent/GB1416018A/en not_active Expired
- 1971-05-05 CA CA112,199A patent/CA985170A/en not_active Expired
- 1971-05-05 NL NLAANVRAGE7106127,A patent/NL173242C/xx not_active IP Right Cessation
- 1971-05-05 FR FR7116224A patent/FR2100631B1/fr not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2900964A1 (de) * | 1978-01-12 | 1979-07-19 | Davide Riccardo Grassetti | Arzneimittel mit einer anregenden wirkung |
| EP0194571B1 (de) * | 1985-03-12 | 1990-11-14 | Hoechst Aktiengesellschaft | Heterocyclische Disulfide, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1416018A (en) | 1975-12-03 |
| FR2100631A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1972-03-24 |
| NL173242C (nl) | 1984-01-02 |
| FR2100631B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-04-18 |
| NL173242B (nl) | 1983-08-01 |
| PH12181A (en) | 1978-11-21 |
| NL7106127A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1971-11-09 |
| ZA712898B (en) | 1973-02-28 |
| IL36587A0 (en) | 1971-08-25 |
| BE766123A (fr) | 1971-09-16 |
| CA985170A (en) | 1976-03-09 |
| IL36587A (en) | 1977-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69909135T2 (de) | Orale zubereitung zur bekämpfung von mundgeruch | |
| DE2628517C2 (de) | Dicarbonsäure-bis(3,5-dicarbamoyl-2,4,6-trijodanilid)-Verbindungen, Verfahren zu ihrer Herstellung und Röntgenkontrastmittel | |
| DE2332878C2 (de) | Salze von Cephalosporinen mit Arginin und Lysin, ihre Herstellung und injizierbare pharmazeutische Zubereitungen | |
| DE3119051A1 (de) | Mittel zur behandlung der augen | |
| DE2948869C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2323187A1 (de) | Verfahren zur herstellung einer stabilisierten, pulverfoermigen secretinzubereitung durch gefriertrocknung | |
| DE2120995A1 (de) | Verfahren zum Modifizieren interzellularer Reaktionen | |
| EP0245669B1 (de) | Pharmazeutisches Präparat zur Verhütung der Schädigung lebender Zellen durch freie Radikale, beziehungsweise zur Erhöhung der Wirksamkeit von organischen Schwefelverbindungen und Verfahren zur Erhöhung der Lebensdauer isolierter Organe | |
| CH615410A5 (en) | Process for the preparation of novel alpha-ethylbenzhydrol derivatives | |
| DE3408362C2 (de) | Arzneimittel mit antineoplastischer Wirkung | |
| DE1695428C3 (de) | Derivate des 5-Mercaptopyridoxins und Verfahren zu deren Herstellung | |
| DE1668385C3 (de) | Quaternare Semicarbazon und Thiosemicarbazon Salze, Verfahren zu deren Herstellung und diese enthalten de pharmazeutische Zusammensetzungen | |
| DE1936723C2 (de) | Salze von Chinarindenalkoloiden und Verfahren zu ihrer Herstellung | |
| DE2243777A1 (de) | Dihydrochinolinderivate, ihre verwendung und verfahren zur herstellung derselben | |
| DE2614138C2 (de) | Benzo[b]thienylcarbonylpropyl- bzw. Butylamine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE3049038C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CH674360A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2401446A1 (de) | Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen | |
| DE1086012B (de) | Verfahren zur Herstellung von protrahiert wirkenden Vitamin-B-Praeparaten | |
| CH634546A5 (de) | Verfahren zur herstellung von komplexen verbindungen von aminodicarbonsaeuren mit magnesium und halogenen. | |
| DE2511576C2 (de) | Metformin-clofibrat, Verfahren zu seiner Herstellung und dieses enthaltendes Arzneimittel | |
| EP0152860B1 (de) | Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems | |
| DE1620177B2 (de) | N-(2-Hydroxyäthyl) -piperazinocarboxymethyl-te tr acy elin, dessen pharmakologisch verwendbaren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE1695043C2 (de) | Pharmazeutische Zusammensetzungen mit sedativen und tranquillisierenden Eigenschaften | |
| CH649536A5 (de) | Wasserloesliche derivate von 6,6'-methylen-bis(2,2,4-trimethyl-1,2-dihydrochinolin) und verfahren zur herstellung derselben. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHW | Rejection |